Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Gift 5 articles to anyone you choose each month when you subscribe. Danish pharmaceutical giant Novo Nordisk says about 13 million Australians are living with obesity or are overweight ...

The pens will be returned to Novo Nordisk's facilities in Denmark – on the same boat that drops them off in the UK – and the plastic will be recycled into a range of items, such as chairs ...

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...

March 5, 2025 Novo Nordisk to sell Wegovy for $499 a month to cash-paying US customers Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $ ...

Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker ...

Mens Novo Nordisk tjener milliarder på fedmemedicin, bliver medicinalgigantens amerikanske medarbejderes pension investeret i junkfood Mens Novo Nordisk tjener styrtende på vægttabsmedicin ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...